NW Bio Phase III trial with DCVax-L for brain cancer commences at King’s College Hospital

DCVax-L mobilizes a cancer patient’s whole immune system to attack the full set of biomarker targets on the tumour.

King’s College Hospital neuro-oncology lead and consultant neurosurgeon Dr. Keyoumars Ashkan said, "The positive data from the clinical trials in the US were very encouraging in delaying disease progression and extending survival times, without significant toxic side effects."

Three other sites in the UK are also preparing to open the trial, and nearly 20 sites in Germany are at different stages of preparation.

Additionally medical centres in other European countries have requested to be added to the trial.

Phase III trial is already going on in the US and is expected to enrol an aggregate total of 312 patients in the US and Europe.

NW Bio CEO Linda Powers said, "This is one of the first late-stage clinical trials with active immune therapies in Europe, and is bringing patients a much needed new treatment option. We are excited to be launching this trial with King’s College Hospital, one of Europe’s premier opinion-leader institutions."

Phase I/II trials demonstrated that in patients treated with DCVax-L the tumours typically did not recur for two years, and the patients typically lived for three years.